Overview

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly inattentive symptoms. The study will also try to evaluate the efficacy of MDX and its level in the blood.

Phase:

Phase 2

Details

Lead Sponsor:

Alcobra Ltd.

Treatments:

Metadoxine
Pyridoxine